Business Wire

BARIATEK-MEDICAL

Share
BariaTek Medical Announces the First-in-Human Implantation of Its BariTon™ Device, a Non-Surgical Gastro-Intestinal Medical Device Aiming to Replicate the Efficacy of Obesity Surgery Without the Invasiveness

BariaTek Medical, a privately held medical device company dedicated to the development of minimally invasive endoscopically delivered solutions to treat obesity and diabetes, founded by Truffle Capital, announced it has initiated enrollment of patients in its First-in-human clinical trial in both Australia and Uzbekistan, and has successfully performed its first-in-human implantation.

Obesity is a chronic and debilitating disease affecting more than one billion people worldwide. It bears a tremendous economic burden to healthcare systems surpassing that of cardiovascular diseases and cancer and its prevalence is increasing worldwide. It often leads to diabetes, high blood pressure, heart disease and reduced life expectancy.

Bariatric surgery currently remains the most effective approach to treat obesity and limits the resulting complications, but surgery is poorly perceived, alters anatomy permanently, is costly, and can result in severe adverse events. Obesity pharmaceutical therapies could provide an effective alternative solution for some patients, but they are very expensive and poorly tolerated in many, resulting in their cessation and corresponding regain of the lost weight. Furthermore, they could be associated with multiple under-reported side-effects and off-label prescriptions. As for available minimally invasive endoscopic solutions, they enjoy variable safety but lack efficacy.

BariaTek Medical’s product candidate, the BariTon™, is a soft, atraumatic, reversible implant that is delivered via a simple endoscopy through the mouth within a few minutes and in an outpatient setting. It consists of a gastric part and an intestinal part, thereby having a dual effect: reduced food intake and calorie absorption. The BariTon™ is expected to be the first implant of its kind to potentially mimic the efficacy of sleeve gastrectomy and bypass surgery1 and offer superior safety, ease of use, reversibility, and lower cost.

Dr. Abdurashid Abdukarimov, Principal Investigator, Bariatric Surgeon at the Center of Surgery in Tashkent Uzbekistan who has led the first human implant said: “I am extremely pleased with the outcome of this first-in-human implantation. The endoscopic procedure was smooth, and the patient recovered very rapidly. She was back at work the day after she was discharged. I would like to thank the support of the BariaTek medical and engineering team, who made the trip to our center, and we look forward to the next steps in this groundbreaking first-in-human study.”

Dr. Adrian Sartoretto, Principal Investigator, Bariatric Endoscopist and Director of the BMI Clinic in Sydney Australia said:The daily life of patients suffering from obesity can be difficult and associated with multiple comorbidities if not treated optimally. The BariTon™ device meets a growing demand for a more innovative, minimally invasive, effective, and reversible solution and we look forward to evaluating its safety and efficacy in our center.

Dr. Thierry Manos and Dr. Christophe Bastid (Marseilles, France), Bariatric Endoscopists and co-inventors of the BariTon™ said: We were delighted to participate in this first-in-human implantation. The procedure went according to plan and we look forward to the outcome of this clinical study.

Youssef Biadillah, CEO of BariaTek Medical said:Obesity is a global pandemic and none of the therapeutic options available today is optimal. We are thrilled about the prospect of bringing our highly differentiated solution, the BariTon™, to obesity gastroenterologists and surgeons and to patients worldwide. More patients need to be treated and carefully monitored and close interactions with regulatory agencies and payors need to take place, to draw conclusions on its safety, efficacy, indications and market potential.

About BariaTek Medical

BariaTek Medical, based in Paris France, is a privately held medical device company dedicated to the development of minimally invasive endoscopically delivered medical devices to treat obesity and limit its complications. BariaTek Medical was founded by Truffle Capital, a premier life science venture capital fund (Paris) and founder (or co-founder) of multiple MedTech and Biotech companies such as Abivax (NASDAQ & Euronext : ABVX), Carmat (Euronext: ALCAR), Carbios (Euronext ALCRB), Vexim (acquired by Stryker), Symetis (acquired by Boston Scientific), Caranx Medical, Artedrone, EvextaBio and Affluent Medical (Euronext: AFME).

1 Sleeve gastrectomy is a surgical procedure consists of removing a large part of the stomach; Bypass bariatric surgery consists of both removing a large part of the stomach and shunting part of the intestine.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240206231942/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting udbygger sine kompetencer inden for cybersikkerhed10.7.2025 02:28:00 CEST | Pressemeddelelse

Andersen Consulting fortsætter med at udvikle sine konsulentydelser med samarbejdsfirmaet IT Security Consulting & Training, et rådgivningsfirma inden for informationssikkerhed med hovedkontor i Jordan. IT Security Consulting & Training blev stiftet i 2011 af administrerende partner Muntaser Bdair og har specialiseret sig i at betjene kunder i den statslige, finansielle og industrielle sektor med ekspertise inden for governance, risk og compliance (GRC), tekniske test, administrerede sikkerhedstjenester, databeskyttelse, cyberresiliens og bredere cybersikkerhedsinitiativer. IT Security Consulting & Training samarbejder med organisationer om at vurdere forretnings- og teknologitrusler, implementere robuste kontroller og opretholde overholdelsen af internationale sikkerhedsstandarder. "Vores mission er at give organisationer mulighed for at opnå det højeste niveau af informationssikkerhed gennem praktisk rådgivning, avanceret uddannelse og skræddersyede sikkerhedsløsninger," siger Muntas

Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development10.7.2025 02:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a global licensing agreement with BeOne Medicines Ltd., a global oncology company, for multiple fully human antibodies. Prior to this licensing agreement, BeOne Medicines had obtained a license to use Biocytogen’s RenMice® fully human antibody platform. Building on this established collaboration, the new agreement expands the partnership into antibody license, further strengthening the strategic relationship between the two companies. Dr. Yuelei Shen, President and CEO of Biocytogen, said, “BeOne Medicines is a global leader in drug development, and we are thrilled to enter into this strategic collaboration. The antibodies licensed under this agreement were discovered using our proprietary RenMice® fully human antibody platform, highlighting o

Andersen Consulting styrker sin tilstedeværelse inden for cybersikkerhed med 10Guards9.7.2025 23:28:00 CEST | Pressemeddelelse

Andersen Consulting udvider sin konsulentkapacitet gennem et samarbejde med 10Guards, en serviceorienteret virksomhed med base i Ukraine, som har specialiseret sig i at levere en bred vifte af professionelle tjenester uden at tilbyde produkter (det være software eller hardware). 10Guards blev stiftet i 2017 og tilbyder skræddersyede cybersikkerhedstjenester, herunder compliance audits, gap assessments og strategisk rådgivning med henblik på at styrke sikkerhedspositionen. De leverer også outsourcet cybersikkerhedssupport gennem virtuelle CISO'er og fulde virtuelle teams, optimering af sikkerhedsdriftscentre (SOC'er) for mere effektiv trusselsdetektering og -respons og etiske hackingtjenester som penetrationstest, social engineering-simuleringer og applikationssikkerhedsvurderinger på tværs af web-, mobil- og cloudmiljøer. "I dagens digitale miljø er cyberresiliens ikke et tilvalg – det er en forudsætning," siger Vitaliy Yakushev, administrerende direktør for 10Guards. "Vores mål er at

IFF to Release Second Quarter 2025 Results on Aug. 5, 20259.7.2025 22:15:00 CEST | Press release

IFF (NYSE:IFF) today announced that it will release its second quarter 2025 earnings results following the market close on Tuesday, Aug. 5, 2025. The management team will host a live webcast on Wednesday, Aug. 6, 2025, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire.com/news/home/20250709408179/en/

Celebrate Excellence: 2026 SPIE Prism Awards Open for Outstanding Photonics Products9.7.2025 18:07:00 CEST | Press release

The winners will be announced 21 January at SPIE Photonics West Applications are now open for the 2026 SPIE Prism Awards. The awards, presented by SPIE, the international society for optics and photonics, recognize the most innovative products on the market, across the growing range of optics and photonics applications. The annual industry event will celebrate its 18th anniversary on 21 January, during a gala evening at SPIE Photonics West. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709679785/en/ SPIE is now welcoming submissions for its 2026 Prism Awards. In 2026, award category areas will include biophotonics instruments, cameras and imaging systems, lasers, optical materials and components, quantum tech, sensors, test and measurement, and XR tech. And now in its third year, SPIE will showcase the SPIE Catalyst Award, recognizing for-profit companies with programs that expand workplace access and opportunity, streng

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye